Hepatitis C Virus Core and Envelope Proteins Do Not Suppress the Host's Ability To Clear a Hepatic Viral Infection (original) (raw)

J Virol. 2001 Dec; 75(24): 11992–11998.

Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas 77555-1070

*Corresponding author. Mailing address: Department of Microbiology and Immunology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-1019. Phone: (409) 747-0186. Fax: (409) 747-6869. E-mail: ude.bmtu@nusij.

Received 2001 Jun 5; Accepted 2001 Sep 14.

Copyright © 2001, American Society for Microbiology

Abstract

Several hepatitis C virus (HCV) proteins have been shown in vitro to interact with host cellular components that are involved in immune regulation. However, there is a paucity of data supporting the relevance of these observations to the in vivo situation. To test the hypothesis that such an interaction suppresses immune responses, we studied a line of transgenic C57BL/6 mice that express the HCV core and envelope proteins in the liver. The potential effects of these proteins on the hepatic immune response were evaluated by challenging these mice with a hepatotropic adenovirus. Both transgenic and nontransgenic mice developed similar courses of infection and cleared the virus from the liver by 28 days postinfection. Both groups of mice mounted similar immunoglobulin G (IgG), IgG2a, interleukin-2, and tumor necrosis factor alpha responses against the virus. Additionally, BALB/c mice were able to clear infection with recombinant adenovirus that does or does not express the HCV core and envelope 1 proteins in the same manner. These data suggest that HCV core and envelope proteins do not inhibit the hepatic antiviral mechanisms in these murine experimental systems and thus favor a model in which HCV circumvents host responses through a mechanism that does not involve general suppression of intrahepatic immune responses.

Hepatitis C virus (HCV), a major cause of chronic liver disease worldwide, currently infects about 1.8% of the U.S. population (1). Most HCV-infected patients become chronically infected, and a substantial proportion of such patients develop clinical manifestations of liver disease. Although the natural history of the chronic infection is not well understood, the high frequency with which infection progresses to chronicity suggests that HCV has evolved specific mechanisms to circumvent the host's immune responses.

A number of distinct models have been proposed to explain the phenomenon of persistent HCV infection. Several studies have described the emergence of viral variants that could escape from the immune system. During the course of a chronic infection, antibodies (Abs) recognizing hypervariable region 1 of the viral E2 envelope protein undergo changes in their epitope specificities. In addition, cytotoxic T lymphocytes (CTL) from a chronically infected chimpanzee failed to recognize the HCV quasispecies present at 4 months postinfection (3, 25). Collectively, these studies suggest that, despite active immune responses, a viral population may emerge with the selection of variants that possess an enhanced ability to persist in the host.

On the other hand, the establishment of a persistent HCV infection may not always be due to genetic variation of the virus (15). It has been suggested that HCV, like adenovirus, herpes simplex virus, and many other viruses, may encode one or more proteins that act to inhibit viral clearance by the host. Indeed, two viral proteins, NS5A and the envelope glycoprotein E2, have been shown to repress the host's double-stranded-RNA-inducible protein kinase R (PKR), resulting in a state of selective interferon (IFN) resistance (7, 21). When expressed in mammalian cells, NS5A confers IFN resistance on vesicular stomatitis virus, which normally is sensitive to the antiviral actions of IFN (6). In addition, the HCV core protein has been shown to bind to the cytoplasmic domains of tumor necrosis factor (TNF) receptor 1, lymphotoxin β receptor, and gC1q receptor (4, 13, 17, 28), resulting in interference with Fas/TNF-α-induced apoptosis and T-cell proliferation in vitro (8, 16).

Given the roles of these cellular proteins in the normal development of peripheral lymphoid organs, transduction of apoptotic signals, and initiation and resolution of inflammation (18, 24), these data raise the possibility that the HCV structural proteins (core, E1, and E2) have significant immunomodulatory functions. However, there is a paucity of data either supporting or refuting the relevance of these in vitro observations to the in vivo situation. To distinguish between the relative contributions of evasive and suppressive factors in HCV persistence in vivo, we took advantage of a recently developed HCV transgenic (tg) mouse (14a) and examined the effects of the HCV structural proteins on intrahepatic immune responses during a viral infection. Our data suggest that the HCV core and envelope proteins are not inherently immunosuppressive in murine experimental systems and thus favor a model in which HCV circumvents immune responses through a mechanism that does not require profound immune suppression.

MATERIALS AND METHODS

Mice.

Generation of HCV tg mice has been described in detail elsewhere (14a). Briefly, cDNA corresponding to the structural protein coding region (core, E1, and E2/p7) of the genotype 1b HCV-N strain of HCV was subcloned into plasmid pGEMAlbSVPA under the control of the liver-specific murine albumin promoter-enhancer. The insert was excised by digestion with _Xho_I and injected into F1 hybrid zygotes (C3H/HeJ × C57BL/6J). The offspring were screened for the presence of tg DNA by Southern blot analysis, and a tg F0 founder (S-N/863) was mated with C57BL/6 mice (H-2b; Jackson Laboratories, Bar Harbor, Maine) to produce F1 and subsequent generations of animals. BALB/c mice (H-2d) were purchased from Jackson Laboratories. All mice were housed in a specific-pathogen-free facility. The Institutional Animal Care and Use Committee of the University of Texas Medical Branch approved the study.

Viral infection of the liver.

Tg and non-tg mice were infected with a replication-impaired (with E1 deleted) adenovirus (Adβgal) that expresses bacterial β-galactosidase (β-Gal), as previously reported by Herz and Gerard (9). Ten tg mice, 2 to 3 months of age, were each inoculated intravenously with 3 × 109 PFU of Adβgal. Equal numbers of age-matched non-tg littermates were infected as controls. In separate experiments, 20 2-month-old female BALB/c mice were similarly infected with 3 × 108 PFU of Adβgal and a recombinant adenovirus expressing the core and E1 segments of the HCV polyprotein (AdCE1) (2). At 3 to 6, 14, and 28 days postinfection, two to four mice in each group were sacrificed by CO2 asphyxiation. Liver tissues were snap frozen in liquid nitrogen for DNA isolation or placed in OCT cryostat-embedding compound (Tissue-Tek, Torrance, Calif.) for morphological analyses. Serum samples were stored at −70°C for subsequent enzyme-linked immunosorbent assays (ELISAs) and alanine aminotransferase (ALT) measurements.

Immunohistochemistry and Western blotting.

After being fixed in acetone and blocked with normal goat serum and avidin-biotin (Avidin/Biotin blocking kit; Vector Laboratories, Burlingame, Calif.), cryosections were incubated at 4°C overnight with a rabbit anti-peptide antibody specific for the E2 protein of HCV-N (1:500). The sections were incubated with biotinylated goat anti-rabbit immunoglobulin G (IgG) followed by avidin-conjugated peroxidase (Vectastain Elite ABC kit) and developed in 3,3′-diaminobenzidine tetrahydrochloride. Detection of lymphocytes in tissue samples was carried out as described previously (20). For immunoblotting, 2 μg of protein extracted from the livers of mice infected with AdCE1 and Adβgal or from a stably transfected cell line, Huh7/191-20, that expresses HCV core, E1, and E2 proteins were electrophoresed in a sodium dodecyl sulfate–12% polyacrylamide gel (unpublished data). The proteins were electrotransferred to a polyvinylidene difluoride membrane (Bio-Rad, Hercules, Calif.) and probed with a mixture of monoclonal Abs (MAbs) specific for HCV core (Anogen, Mississauga, Canada), β-actin (Sigma, St. Louis, Mo.), and adenovirus hexon protein (Chemicon, Temecula, Calif.), followed by a horseradish peroxidase-conjugated anti-mouse IgG (Southern Biotechnology Associates, Birmingham, Ala.) and enhanced chemiluminescence detection reagents (Amersham Pharmacia Biotech, Little Chalfont, England).

Detection of Adβgal in liver cryosections.

Following a brief fixation with 0.5% glutaraldehyde, frozen liver sections were incubated with 0.2 mg of X-Gal (5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside)/ml at 37°C for 60 to 120 min. Infected cells expressing β-Gal activity were stained blue, whereas uninfected cells were counterstained red (neutral red). Five images from two liver sections were randomly selected and captured with a Zeiss Axioskop microscope equipped with a Sony DXC-970MD video camera (10× objectives). Infected and uninfected regions were quantified using the MetaView Imaging System 4.0 software (Universal Imaging System, West Chester, Pa.). Thresholds were selected with colors representative of the desired color range of the infected or uninfected cells. Infectivity of the hepatocytes was expressed as the average ratio of infected to uninfected cells.

Determination of hepatic viral load.

The Adβgal copy numbers in the liver were assessed by real-time quantitative PCR. Total DNA was extracted from 50 mg of liver tissue from each mouse by using a QIAamp DNA Mini Kit (Qiagen Inc., Valencia, Calif.). Analysis was carried out on a Roche LightCycler with its core reagent kit (DNA Master SYBR Green 1). The PCR primers corresponding to the adenovirus hexon gene were 5′-GAGCCAGCATTAAGTTTGATAGCA-3′ and 5′-AGATAGTCGTTAAAGGACTGGTCGTT-3′. The extracted DNA samples were diluted 1:100 with Tris-EDTA buffer, and 5-μl aliquots were placed in glass capillary cuvettes (Roche) containing 15 μl of PCR master mix. Reaction cycles included denaturation at 94°C for 30 s, annealing at 60°C for 5 s, and extension at 72°C for 10 s. The reaction produced a 126-bp product. The observed threshold cycle for a no-template control was typically around 35 cycles. The standard curve of the threshold cycles versus the template abundance was linear over 5 orders of magnitude, with a regression correlation typically greater than 0.98. All data were combined from two independent experiments.

Measurements of serum IgG and cytokines.

Serum samples were analyzed for adenovirus-specific IgG by ELISA with a procedure modified from a previous report by Chirmule et al. (5). Briefly, 96-well Immunolon-IV microtiter plates (Dynatech, Chantilly, Va.) were coated with Adβgal (108 particles/ml). Serum dilutions (1:50) were added to duplicate wells, and the plates were incubated at 4°C overnight. The plates were incubated with biotinylated rabbit anti-mouse IgG or IgG2a, followed by avidin-conjugated peroxidase (BD PharMingen). The enzyme activity was determined calorimetrically using _O_-phenylenediamine dihydrochloride reagent (Sigma) and read at 492 nm. Interleukin-2 (IL-2) and TNF-α in the serum samples were measured with commercial ELISA kits (BD PharMingen) according to the manufacturer's recommendations. The paired MAbs specific for IL-2 and TNF-α were JES6-1A12/JES6-5H4 and G281-2626/MP6-XT3, respectively. Serum samples (1:3) were incubated in the plates at 4°C overnight, followed by incubation with a biotinylated anti-IL-2 or anti-TNF-α MAb. Avidin-conjugated peroxidase was added to the plates, and the enzyme activity was determined calorimetrically as described above.

TUNEL assay for detection of apoptosis in situ.

The terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assay was carried out on deparaffinized, formalin-fixed liver sections treated with proteinase K (20 mg/ml). After endogenous peroxidase was blocked by immersing the sections in 3% H2O2 for 30 min, slides were incubated with a buffer solution containing terminal deoxynucleotide transferase and digoxigenin-labeled deoxynucleotide triphosphates (ApopTag Peroxidase; Intergen Company, Purchase, N.Y.) in a humidified chamber at 37°C for 1 h. An antidigoxigenin-peroxidase conjugate was added for 30 min, followed by 3,3′-diaminobenzidine tetrahydrochloride as a chromogen. The slides were scored blindly with respect to the tg status of the animal. One section from each mouse was examined in each of two independent assays. The total number of apoptotic cells in 10 randomly selected microscopic fields (40×) was scored in each section.

Statistical analysis.

All statistical evaluations were conducted using analysis of variance for two factors, independently and interactively. Tabulations were facilitated by using Abstat 1.90 software (Anderson-Bell Corp., Arvada, Colo.).

RESULTS

Since the intrahepatic immune system has a number of unique properties, including lymphocyte populations that are distinct from those of the spleen and lymph nodes (19), it is important to examine the potential immunosuppressive effects of HCV proteins in the context of the hepatic microenvironment. To assess the role of HCV structural proteins expressed at levels similar to those encountered in infected humans, we used a tg mouse line with liver-specific expression of HCV core, E1, and E2/p7 proteins. Immunocompetent mice are capable of eliminating recombinant adenovirus primarily through a cellular immune response (27, 29). Thus, the prolonged presence of adenovirus in these tg mice would support the view that the HCV structural proteins suppress the immune system.

First, we evaluated the expression of the HCV transgene in the tg mice. The E2 protein was expressed in tg liver tissue with a distribution that was cytoplasmic and particularly prominent in the pericentral regions (Fig. ​1A). No E2 antigen was present in non-tg mice. RNA transcripts of the transgene were detectable in the livers of tg mice by Northern blot analysis (14a). Next, we infected these mice and their non-tg littermates with a recombinant adenovirus (Adβgal) that expresses a reporter β-Gal. When 3 × 109 PFU of Adβgal was injected through the tail vein, the hepatotropism of the virus was evidenced by β-Gal staining of the liver but not the spleen, kidneys, or lungs (data not shown). Three groups of mice in each of two experiments were sacrificed during the early (days 3 to 6), intermediate (day 14), and late (day 28) stages of the infection. Both tg and non-tg mice demonstrated a striking hepatic infection during the early stage (Fig. ​1B). The β-Gal activity was easily detectable in infected hepatocytes, and the excellent contrast between β-Gal and neutral red (counterstain) allowed accurate enumeration of infected hepatocytes. The results from these experiments showed that tg and non-tg mice followed similar courses of infection, with the disappearance of most Adβgal-infected hepatocytes by 28 days postinfection (Fig. ​1B and ​2A). To provide an independent measure of viral clearance, we also determined the viral load in the liver tissues by a highly sensitive real-time quantitative PCR. Consistent with functional loss of viral β-Gal activity, there was an average of 90 and 94% reduction of the viral genome in tg and non-tg mice, respectively, by 28 days postinfection (Fig. ​2B). At about 30 viral particles per cell in both groups of animals, these viral loads may draw near the threshold of the lacZ assay (Fig. ​2A) and thus prohibit further identification of infected cells beyond that point. Together, these results demonstrated no impairment in the ability of the HCV tg mice to respond to and successfully eliminate an intrahepatic infection with an unrelated virus.

An external file that holds a picture, illustration, etc. Object name is jv2411085001.jpg

Histochemical and immunohistochemical staining of liver samples from HCV tg (Tg+) and non-tg (Tg−) mice. (A) Livers from a non-tg mouse (C57BL/6J) and an HCV tg mouse stained for HCV E2 antigen. Liver sections were stained as described in Materials and Methods. The tg mouse demonstrated cytoplasmic distribution of specific E2 antigen (40× objective). Parallel staining using rabbit antibody specific for an irrelevant antigen (a salivary protein of the sand fly Lutzomyia longipalpis) revealed no positively stained cells in either tg or non-tg mice (data not shown). (B) β-Gal expression in hepatocytes at 3, 14, and 28 days following infection with Adβgal. Mice were injected with 3 × 109 PFU of Adβgal suspended in 100 μl of PBS via the tail vein. Liver sections were stained with X-Gal and counterstained with neutral red, staining infected hepatocytes blue and uninfected hepatocytes red. (C) T-cell recruitment to inflammatory lesions in the livers of Adβgal-infected mice at 3 days postinfection. Sections were incubated at 4°C overnight with a biotinylated MAb specific for mouse CD4 or CD8 (1:500), followed by avidin-conjugated peroxidase. Representative photomicrographs are shown.

An external file that holds a picture, illustration, etc. Object name is jv2411085002.jpg

Clearance of intrahepatic Adβgal infection in mice. (A) Liver sections were stained with X-Gal as described in the legend to Fig. ​2A. Image analysis was used to assess the extent of Adβgal infection. The data points represent the average ratio of infected to uninfected hepatocytes from individual mice. While the percentage of infected cells continued to decrease (P < 0.01), the pattern of decline in both groups of mice remained the same (_P_ > 0.05). No significant difference was found between tg (Tg+) and non-tg (Tg−) mice (P > 0.05). (B) Adβgal genome abundance in livers of infected mice as determined by real-time quantitative PCR analysis (see Materials and Methods). No difference in viral load, either overall (P > 0.05) or at any given date (P > 0.05), was found between the two groups of mice. The viral load decreased significantly during the course of infection in both groups of mice (P < 0.01). In both panels, the data points were derived from two independent experiments.

Since both humoral and cellular immune responses have been demonstrated to play critical roles in adenovirus clearance and recovery from experimental adenovirus infections (10, 27, 29), we examined whether these responses to the viral infection were quantitatively affected in tg mice. Despite the expression of the HCV structural proteins in tg animals, tg and non-tg mice produced similar quantities of adenovirus-specific IgG, as well as IgG2a, which is generally accepted as an indicator of the Th1-mediated immune response (Fig. ​3A and B). Immunohistological examinations showed that the two groups of mice had comparable abilities to recruit CD4 and CD8 T cells to inflammatory lesions in the liver (Fig. ​1C). Also, the serum levels of TNF-α and IL-2 in tg mice were equivalent to those found in non-tg littermates (Fig. ​3C and D), suggesting no apparent compromise in either the humoral or cellular effector mechanisms.

An external file that holds a picture, illustration, etc. Object name is jv2411085003.jpg

Production of virus-specific IgG and cytokines following an intrahepatic viral infection. Mice were injected with Adβgal as for Fig. ​2A, and their serum samples were collected at the indicated time points. The error bars represent the standard deviations among individual animals. The relative concentrations of virus-specific IgG (A) and IgG2a (B) are expressed as absorbance, or optical density (O.D.). The figures are representative of two or three experiments with similar results. The levels of circulating TNF-α (C) and IL-2 (D) were determined by ELISA. Tg+, tg mice; Tg−, non-tg mice.

In immunocompetent mice, adenovirus infection of the liver is accompanied by a transient elevation of serum ALT activity, which is followed by a significant reduction in virus within 3 weeks (27). Thus, we determined whether the presence of the HCV structural proteins was associated with exacerbated liver injury and/or delayed resolution of the biochemical lesion. The peak of the chemical liver injury occurred at 14 days postinfection in both tg and non-tg mice, and ALT levels declined significantly in both groups of animals thereafter (Fig. ​4A). The resolution of hepatic inflammation in both groups of mice was also confirmed by measurements of the total liver weight, as well as resolution of acute histopathological abnormalities (data not shown). Since the tg mice demonstrated robust TNF-α production in response to Adβgal infection (Fig. ​3C), we also examined the possibility that expression of the HCV core protein in the liver could result in an exacerbated TNF-induced apoptosis in the tg mice (4, 8, 17, 28). Using TUNEL assays, we found that both tg and non-tg mice had elevated numbers of apoptotic cells in the liver during the early stages of infection. However, the number of apoptotic cells declined in both groups as the infection progressed to the later stages (Fig. ​4B). There were no significant differences between tg and non-tg animals in these studies.

An external file that holds a picture, illustration, etc. Object name is jv2411085004.jpg

Recovery from liver injury following Adβgal infection in HCV tg (Tg+) and non-tg (Tg−) mice. The experiments were carried out as described in the legend to Fig. ​2A. (A) Serum ALT levels are shown in individual animals as a function of time following infection. There was no significant difference in ALT values between tg and non-tg mice (P > 0.05). (B) TUNEL assay for detection of apoptosis in the liver. Shown are the numbers of apoptotic cells present in 10 randomly selected fields (magnification, ×40) in individual sections. No difference in the number of apoptotic cells, either overall (P > 0.05) or at any given time point (P > 0.05), was found between two groups of mice. The number of apoptotic cells decreased significantly during the course of infection in both groups of mice (P < 0.01). The slides were scored blindly for apoptotic cells with respect to the date and tg status of the animal.

To determine whether the absence of immunosuppression due to HCV structural proteins that we observed in the HCV tg mice could be restricted to the H-2b/k genetic background or the level of tg expression, we infected BALB/c (H-2d) mice with 3 × 108 PFU of Adβgal and a recombinant adenovirus (AdCE1) expressing the core and E1 segments of the HCV genome (2). Such infection resulted in a substantially higher abundance of the intracellular HCV core protein (Fig. ​5A). Despite this, we observed a significant reduction of viral load in the BALB/c mice infected with AdCE1, which was comparable to that in the mice infected with Adβgal (Fig. ​5B). Both groups of mice recovered from the infection, as reflected in a decrease in serum ALT activities from early peak values (data not shown). These results lend strong support to the conclusion that in mice the HCV core protein does not hinder the host's ability to resolve an intrahepatic viral infection. This absence of immunosuppression is neither mouse strain specific nor dependent on the level of HCV core expression.

An external file that holds a picture, illustration, etc. Object name is jv2411085005.jpg

Clearance of intrahepatic Adβgal and AdCE1 infections in BALB/c mice. (A) Immunoblot detection of the HCV core protein in the liver of an AdCE1-infected mouse. Huh7/191-20 is a stably transfected cell line that expresses the HCV core, E1, and E2 proteins (see Materials and Methods). Probing was carried out with a mixture of MAbs specific for HCV core, β-actin, and adenovirus hexon protein, followed by a horseradish peroxidase-conjugated anti-mouse IgG. (B) Adβgal and AdCE1 copy numbers in the liver DNA extracts were assessed by real-time quantitative PCR analysis, as described in the legend to Fig. ​2B. All data points represent an average of two or three animals in each group, and the error bars depict standard deviations.

DISCUSSION

Using a series of vaccinia virus/HCV recombinants, Large et al. have examined the influence of specific HCV gene products on the immune responses to vaccinia virus in a murine model (14). In that study, vaccinia virus recombinants expressing various regions of the HCV polyprotein were inoculated intraperitoneally into naïve BALB/c mice. The HCV core protein contributed to a greater pathogenicity of vaccinia virus/HCV recombinants in BALB/c mice (H-2d), suggesting that it might contribute to viral persistence by directly suppressing host immune responses, in particular, the generation of virus-specific CTL. In the present study, however, we evaluated the effect of the HCV core protein in tg mice that express an abundance of the HCV structural proteins that is much closer to that found in infected human livers. Surprisingly, we found no evidence of suppression of intrahepatic viral clearance mechanisms in these mice (H-2b/k) by the HCV core, E1, or E2 protein. Mice from a genetically different background (H-2d) also efficiently cleared a recombinant adenovirus that expressed a much higher level of the HCV core protein. Mice from both genetic backgrounds made timely recoveries from the intrahepatic infection. The absence of demonstrable immunosuppression cannot be attributed to the lack of a need for effective immune responses to clear a recombinant adenovirus, since persistence of the virus has been demonstrated in nude mice by Southern blot analysis and β-Gal histochemistry for up to 60 days postinfection (26, 29). In addition, administration of immunosuppressants, such as FK506, cyclosporine A, dexamethasone, or Ab-soluble fusion protein blocking CD40 ligand, has been shown to significantly prolong the presence of the virus in infected mouse liver (12, 23, 29). In patients with hepatitis C, HCV RNA is typically detectable only by RT-PCR, and demonstration of viral proteins in the liver is often difficult. Thus, the demonstration of HCV mRNA transcripts in the tg mice coupled with evidence of polyprotein expression and steatosis (14a) indicates that the abundance of HCV proteins expressed in tg mice was adequate for the intended purpose of this study.

The difference between our results and those of Large et al. (14) may be in the type of challenge infection. Vaccinia virus can replicate in the ovaries and spleen in addition to the liver in mice. The greater pathogenicity of the core-expressing vaccinia virus was found by Large et al. to be associated with progressive lytic infection and necrosis in those organs (14). In contrast, the mice used in our study were challenged with a recombinant adenovirus that is highly hepatotropic when inoculated through the tail vein. Such an experimental system is more likely to reflect the situation existing in the HCV-infected livers of patients.

Apoptosis has been suggested as a common pathway to virus clearance by host CTL and NK cells. Many virus genomes encode proteins that suppress apoptosis in order to escape immune attack by the host (18). Conflicting results have suggested that the HCV core protein can either protect transfected cells from Fas- and TNF-α-induced apoptotic cell death or sensitize them to it (8, 16, 28). Our results suggest that HCV core neither exacerbates nor inhibits apoptosis in vivo in the face of a robust, endogenous TNF-α response. Furthermore, as our tg-mouse experiments have shown, the HCV E2 protein does not hamper the host's ability to mount effective intrahepatic immune responses, even though it has been suggested to interfere with and suppress PKR responses (21).

These data clarify previous contradictory reports regarding the functions of core and E2 proteins, as they are derived from an in vivo system in which the abundances of these proteins are more reflective of the situation in human patients. While our data favor a model in which HCV circumvents the immune responses through a mechanism that does not involve general immunosuppression, they do not exclude the possibility that the virus modulates the complex interplay between the dynamics of viral diversity and the early breadth of CTL responses. For instance, viral escape mutants have been shown to give rise to T-cell receptor antagonists capable of inhibiting CTL clones that recognize prototypic viral epitopes (3, 11, 22). In addition, the additive or synergistic effects of other HCV proteins not expressed in these studies (e.g., NS5A) may conceivably contribute to viral resistance to the IFN-mediated antiviral mechanism, leading to persistent infection (7).

ACKNOWLEDGMENTS

We gratefully acknowledge Tony Carroll at Glaxo Wellcome for providing AdCE1 virus, Kui Li for providing Huh7/191-20 cells, Elbert Whorton for statistical analysis, Shu-Yuan Xiao for evaluating histopathological sections, Hong Diao for excellent technical assistance, Chiaho Shih for critical reading of the manuscript, and Mardelle Susman for assistance with manuscript preparation.

This work was supported by grants from the National Cancer Institute (SBIR-CA88770), the National Institute of Allergy and Infectious Diseases (U19-AI40035), and the John Sealy Memorial Endowment Fund for Biomedical Research.

REFERENCES

1. Alter M J, Kruszon-Moran D, Nainan O V, McQuillan G M, Gao F, Moyer L A, Kaslow R A, Margolis H S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562. [PubMed] [Google Scholar]

2. Bruna-Romero O, Lasarte J J, Wilkinson G, Grace K, Clarke B, Borras-Cuesta F, Prieto J. Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology. 1997;25:470–477. [PubMed] [Google Scholar]

3. Chang K M, Rehermann B, McHutchison J G, Pasquinelli C, Southwood S, Sette A, Chisari F V. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Investig. 1997;100:2376–2385. [PMC free article] [PubMed] [Google Scholar]

4. Chen C M, You L R, Hwang L H, Lee Y H. Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-β receptor modulates the signal pathway of the lymphotoxin-β receptor. J Virol. 1997;71:9417–9426. [PMC free article] [PubMed] [Google Scholar]

5. Chirmule N, Truneh A, Haecker S E, Tazelaar J, Gao G, Raper S E, Hughes J V, Wilson J M. Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody. J Immunol. 1999;163:448–455. [PubMed] [Google Scholar]

6. Gale M, Jr, Kwieciszewski B, Dossett M, Nakao H, Katze M G. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol. 1999;73:6506–6516. [PMC free article] [PubMed] [Google Scholar]

7. Gale M J, Jr, Korth M J, Tang N M, Tan S L, Hopkins D A, Dever T E, Polyak S J, Gretch D R, Katze M G. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 1997;230:217–227. [PubMed] [Google Scholar]

8. Hahn C S, Cho Y G, Kang B S, Lester I M, Hahn Y S. The HCV core protein acts as a positive regulator of Fas-mediated apoptosis in a human lymphoblastoid T cell line. Virology. 2000;276:127–137. [PubMed] [Google Scholar]

9. Herz J, Gerard R D. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA. 1993;90:2812–2816. [PMC free article] [PubMed] [Google Scholar]

10. Jooss K, Ertl H C, Wilson J M. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol. 1998;72:2945–2954. [PMC free article] [PubMed] [Google Scholar]

11. Kaneko T, Moriyama T, Udaka K, Hiroishi K, Kita H, Okamoto H, Yagita H, Okumura K, Imawari M. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope. Eur J Immunol. 1997;27:1782–1787. [PubMed] [Google Scholar]

12. Kay M A, Meuse L, Gown A M, Linsley P, Hollenbaugh D, Aruffo A, Ochs H D, Wilson C B. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA. 1997;94:4686–4691. [PMC free article] [PubMed] [Google Scholar]

13. Kittlesen D J, Chianese-Bullock K A, Yao Z Q, Braciale T J, Hahn Y S. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Investig. 2000;106:1239–1249. [PMC free article] [PubMed] [Google Scholar]

14. Large M K, Kittlesen D J, Hahn Y S. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol. 1999;162:931–938. [PubMed] [Google Scholar]

14a. Lerat, H., M. Honda, M. Beard, K. Loesch, J. Sun, Y. Yang, M. Okuda, R. Gosert, S. Y. Xiao, S. A. Weinman, and S. M. Lemon. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology, in press. [PubMed]

15. Major M E, Mihalik K, Fernandez J, Seidman J, Kleiner D, Kolykhalov A A, Rice C M, Feinstone S M. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol. 1999;73:3317–3325. [PMC free article] [PubMed] [Google Scholar]

16. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-κB activation. J Virol. 1999;73:4713–4720. [PMC free article] [PubMed] [Google Scholar]

17. Matsumoto M, Hsieh T Y, Zhu N, VanArsdale T, Hwang S B, Jeng K S, Gorbalenya A E, Lo S Y, Ou J H, Ware C F, Lai M M. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-β receptor. J Virol. 1997;71:1301–1309. [PMC free article] [PubMed] [Google Scholar]

18. Moretta A. Molecular mechanisms in cell-mediated cytotoxicity. Cell. 1997;90:13–18. [PubMed] [Google Scholar]

19. O'Farrelly C, Crispe I N. Prometheus through the looking glass: reflections on the hepatic immune system. Immunol Today. 1999;20:394–398. [PubMed] [Google Scholar]

20. Sun J, Tarleton R L. Predominance of CD8+ T lymphocytes in the inflammatory lesions of mice with acute Trypanosoma cruzi infection. Am J Trop Med Hyg. 1993;48:161–169. [PubMed] [Google Scholar]

21. Taylor D R, Shi S T, Romano P R, Barber G N, Lai M M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999;285:107–110. [PubMed] [Google Scholar]

22. Tsai S L, Chen Y M, Chen M H, Huang C Y, Sheen I S, Yeh C T, Huang J H, Kuo G C, Liaw Y F. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology. 1998;115:954–965. [PubMed] [Google Scholar]

23. Vilquin J T, Guerette B, Kinoshita I, Roy B, Goulet M, Gravel C, Roy R, Tremblay J P. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther. 1995;6:1391–1401. [PubMed] [Google Scholar]

24. von Boehmer H. Lymphotoxins: from cytotoxicity to lymphoid organogenesis. Proc Natl Acad Sci USA. 1997;94:8926–8927. [PMC free article] [PubMed] [Google Scholar]

25. Weiner A, Erickson A L, Kansopon J, Crawford K, Muchmore E, Hughes A L, Houghton M, Walker C M. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA. 1995;92:2755–2759. [PMC free article] [PubMed] [Google Scholar]

26. Yang Y, Nunes F A, Berencsi K, Gonczol E, Engelhardt J F, Wilson J M. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet. 1994;7:362–369. [PubMed] [Google Scholar]

27. Yang Y, Nunes F A, Berencsi K, Furth E E, Gonczol E, Wilson J M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 1994;91:4407–4411. [PMC free article] [PubMed] [Google Scholar]

28. Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C, Lai M M. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol. 1998;72:3691–3697. [PMC free article] [PubMed] [Google Scholar]

29. Zsengeller Z K, Wert S E, Hull W M, Hu X, Yei S, Trapnell B C, Whitsett J A. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther. 1995;6:457–467. [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)